| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081, 2019 | 309 | 2019 |
| Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial V Diéras, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... The lancet oncology 21 (10), 1269-1282, 2020 | 267 | 2020 |
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, ... Clinical Cancer Research 18 (6), 1726-1734, 2012 | 228 | 2012 |
| Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients P Wang, A Bahreini, R Gyanchandani, PC Lucas, RJ Hartmaier, ... Clinical cancer research 22 (5), 1130-1137, 2016 | 215 | 2016 |
| Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis ME Klein, DJ Dabbs, Y Shuai, AM Brufsky, R Jankowitz, SL Puhalla, ... Modern Pathology 26 (5), 658-664, 2013 | 200 | 2013 |
| Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ... AMER SOC CLINICAL ONCOLOGY, 2019 | 178 | 2019 |
| Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized … HS Han, V Diéras, M Robson, M Palácová, PK Marcom, A Jager, ... Annals of Oncology 29 (1), 154-161, 2018 | 177 | 2018 |
| Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2–positive breast cancer and … RA Freedman, RS Gelman, JS Wefel, ME Melisko, KR Hess, RM Connolly, ... Journal of Clinical Oncology 34 (9), 945, 2016 | 167 | 2016 |
| ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases P Kumthekar, SC Tang, AJ Brenner, S Kesari, DE Piccioni, C Anders, ... Clinical Cancer Research 26 (12), 2789-2799, 2020 | 163 | 2020 |
| Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases N Priedigkeit, RJ Hartmaier, Y Chen, D Vareslija, A Basudan, RJ Watters, ... JAMA oncology 3 (5), 666-671, 2017 | 160 | 2017 |
| Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models A Bahreini, Z Li, P Wang, KM Levine, N Tasdemir, L Cao, HM Weir, ... Breast Cancer Research 19, 1-10, 2017 | 141 | 2017 |
| Hormonal therapy in breast cancer: a model disease for the personalization of cancer care S Puhalla, S Bhattacharya, NE Davidson Molecular oncology 6 (2), 222-236, 2012 | 113 | 2012 |
| Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer RJ Hartmaier, SE Trabucco, N Priedigkeit, JH Chung, CA Parachoniak, ... Annals of oncology 29 (4), 872-880, 2018 | 103 | 2018 |
| Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets D Varešlija, N Priedigkeit, A Fagan, S Purcell, N Cosgrove, PJ O’Halloran, ... JNCI: Journal of the National Cancer Institute 111 (4), 388-398, 2019 | 94 | 2019 |
| Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast … S Puhalla, JH Beumer, S Pahuja, LJ Appleman, HAH Tawbi, RG Stoller, ... Journal of Clinical Oncology 32 (15_suppl), 2570-2570, 2014 | 82 | 2014 |
| Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast … S Puhalla, JH Beumer, S Pahuja, LJ Appleman, HAH Tawbi, RG Stoller, ... Journal of Clinical Oncology 32 (15_suppl), 2570-2570, 2014 | 82 | 2014 |
| The molecular landscape of premenopausal breast cancer S Liao, RJ Hartmaier, KP McGuire, SL Puhalla, S Luthra, UR Chandran, ... Breast Cancer Research 17, 1-13, 2015 | 77 | 2015 |
| Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer S Wilks, S Puhalla, J O'Shaughnessy, L Schwartzberg, E Berrak, J Song, ... Clinical Breast Cancer 14 (6), 405-412, 2014 | 76 | 2014 |
| Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer S Wilks, S Puhalla, J O'Shaughnessy, L Schwartzberg, E Berrak, J Song, ... Clinical Breast Cancer 14 (6), 405-412, 2014 | 76 | 2014 |
| BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different M Burgess, S Puhalla Frontiers in oncology 4, 19, 2014 | 74 | 2014 |
